NFKB1 and breast carcinoma: To address whether lapatinib can induce NF-κB activation in both HER2-positive and HER2-negative breast cancer cells, its effect on p65 Ser536 phosphorylation, a critical IKK complex-mediated modification for NF-κB activity [25], was examined.